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Fig. S1. DNA vaccine design and antigen expression. targets pulsed with 10ug/ml of ZIKV NS1 Pool 3 in representative mice from groups vaccinated with pVAX, pVAX-NS1, pVAX-tpaNS1 and pVAXtpaNS1-IMX313P
Fig. S3. Epitope confirmation.
Groups of Balb/c mice (n = 6-7/ group) were vaccinated with NS1 DNA vaccine constructs three times at 2-week intervals and 13 days after the last vaccine dose FTA assay was performed. In vivo cell killing was measured against targets pulsed with ZIKV NS1 pool 4 peptides without CTL ID peptides (87 and 88). Peptide pulsed and mock target cells (1.5 x10 6 for each target cell cluster) were injected i.v. into vaccinated mice and splenocytes harvested 15h later and analysed by flow cytometry. % specific killing was calculated for the ZIKV NS1 CTL epitopes above mock. Data shows mean +/-SEM of NS1-specific CTL killing.
Fig. S4
. ZIKV viral load over time in T cell-depleted mice. Serum viral loads in pVAX-tpaNS1 DNA vaccinated mice that were undepleted or depleted of CD4 + and/or CD8 + T lymphocytes prior to challenge with ZIKVZKV2015. Serum ZIKV viral loads (mean (n=10 ) ± SEM) on days 1, 3 and 7 post challenge are shown. pVAX immunised mice were used as controls.
